Summary A total of 8,427 women with breast cancer with height and weight measured prior to the diagnosis were followed up for on average 4.3 years. 2,383 women died from breast cancer and 430 from other causes. Among women diagnosed without any metastasis (stage I) the death rate was 1.70 times higher for those belonging to the highest quintile of body mass with respect to age compared to those in the lowest quintile. For patients with involved lymph nodes at diagnosis (stage II) the death rate was 1.42 times higher. Overweight was not a prognostic factor for stages III and IV patients. The prognostic effect of body mass in stages I and II was mainly connected to those in the highest quintile and was found for women in pre-as well as post-menopausal age. The effect did not depend on the length of time between measurement and diagnosis. Height was not found to be of prognostic relevance. The idea of the feasibility of a dietary trial in terms of the minimum trial size is given.
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In a recent study of the relation between height and weight and breast cancer morbidity (Tretli, 1989) , height was found to be a risk factor independent of age. Overweight was a risk factor in the post-menopausal age-group while it appeared to protect against breast cancer in the pre-menopausal agegroup. When stage I and stages II-IV were used as followup endpoints, a negative and positive association, respectively, with overweight was found indicating that overweight reflects enhanced growth. A reasonable extension of this study was to use the same series to look at premorbid height and weight as possible prognostic factors for the outcome of the disease. Most studies on the subject have shown that overweight aggravates the prognosis of breast cancer patients (Rose & Boyar, 1986) . Height, however, has not been shown to be a prognostic factor (De Waard, 1986) .
The size of our series is much greater than that of previous studies. This allows an analysis within each of the four stages of the disease. In this study we pay special attention to the fact that overweight ought to be considered relative to the person's age at time of measurement and we look for feasible weight groups with respect to possible dietary intervention trials. As a measure of obesity we have used Quetelet's index which is defined as weight divided by the height squared. This index has been shown to be strongly correlated to weight and almost uncorrelated to height (Benn, 1971 (UICC, 1968) .
Materials and methods
We felt that both height and Quetelet's index should be related to the woman's age, height because of a strong birth-cohort effect (Figure la) The analysis is done within subgroups defined by the stage of the disease at time of diagnosis. The statistical package BMDP (1985) was used in the analysis. The adequacy of the proportional hazards assumptions in the regression models were checked by In(-ln)-plots from stratified analysis for the variables included as covariates (Kalbfleisch & Prentice, 1980) and the assumptions were accepted.
The estimations of the sample size of a possible intervention trial are based on log rank statistics (Freedman, 1982 Height is known to be a risk factor for breast cancer, but not a prognostic factor (De Waard, 1986) . We found no prognostic effect of height in this study.
Quetelet's index appears to be a prognostic factor for breast cancer diagnosed in stage I or II of the disease but not for stages III and IV. Table I shows that the prognostic effect of the relative Quetelet's index is mainly connected to the highest quintile of the distribution. This means that there is a Figure 2a, Months after diagnosis Age 65+ years groups: 0-12 months, 13-59 months and 60 + months. The result (not demonstrated) shows no significant impact of this variable.
It has been claimed that the prognostic effect of overweight valid is for post-menopausal women only. A sub-group analysis by age does not confirm this point of view. The estimated prognostic effect of Quetelet's index was similar to the result shown in Table I for each of the three age-groups decribed in the model.
We also carried out a survival analysis when only the time interval from 24 months after diagnosis is taken into account. This implies that we are 'excluding' events in the active period of treatment. The result reveals that the prognostic effect of Quetelet's index in the fifth quintile becomes a little stronger (not shown). Table II shows a significant positive association between tumour size and Quetelet's index (P = 0.015) obtained in the separate study. This study made it possible to check the quality of the Cancer Registry's staging of the patients (used in the main study) versus the clinical notes. The comparison reveals complete accordance.
We have made some computations to get an idea of the size of an intervention trial organised as a randomised twogroup study among women belonging to the fifth quintile of the Quetelet's index. Table III shows the number needed and the minimim size of the background breast cancer population for four trial designs.
Discussion
We found that death from other diseases was less frequent in breast cancer cases than in the general population when age and year of birth are taken into account. This may be explained by the fact that high socio-economic status is positively associated with breast cancer (Rimpela & Pukkala, 1987) and negatively associated with most other diseases than breast cancer (Borgan & Kristofersen, 1986) . Overweight persons have a higher mortality in general and especially an excess mortality from cerebrovascular disease and diabetes (Waaler, 1984) . The observed mortality from cerebrovascular disease and 'other disease' (including diabetes) was 137 versus 179.3 cases expected. It is unlikely that this difference, taking into account that 2,383 patients died from breast cancer, could significantly influence our results. A high Quetelet's index was associated with a poorer prognosis. This is in accordance with previous studies by Boyd et al. (1981) , Newman et al. (1986) and Hebert et al. (1988) . Tartter et al. (1981) and Greenberg et al. (1985) reported that patients with high Quetelet's index fare worst, but their results were not statistically significant. However, they found a significant relationship between overweight and bad prognosis. The prognostic effect of Quetelet's index in this study is present only in stages I and II, which comprise 81% of all our cases. The highest risk is seen among patients belonging to the highest quintile of the distribution of Quetelet's index. For stage III and IV (13% of the patients) no prognostic effect of Quetelet's index could be seen. This is in accordance with Boyd et al. (1981) who concluded that the prognostic effect was generally most marked in patients with a tumour the prognostic characteristics of which were favourable. Similar findings were reported by Newman et al. (1986) and Hebert et al. (1988) and by Donegan et al. (1978) who included weight but not Quetelet's index in the analysis. Hebert et al. explained why the effect of overweight is seen among women with early-stage disease by the fact that the effect of overweight is more strongly expressed against the background of a set of relatively weaker prognostic factors.
Another explanation may be that the staging was faulty. Staging is a type of elimination procedure. Stage IV patients and also the majority of patients in stage III have clear diagnostic characteristics. All patients who do not fulfil the criteria for stages III or IV will be in stage II if positive lymph nodes are found and in stage I if not. If there are circumstances connected to overweight women that make the staging procedure more difficult, for example, if it was more difficult to find regional lymph nodes or distant metastases, then the stage classification will be too low which will result in a spurious prognostic effect of overweight. For example, if about 15% of the stage I patients in the highest quintile-group of Quetelet's index were really in stage II and about 20% of the stage II patients in the highest quintile group were stage IV patients, this could explain approximately the observed prognostic effect of being in the highest quintile group of Quetelet's index. It seems improbable that the diagnostic problems connected with overweight are of such a magnitude.
A third explanation may be, at least in part, that in overweight women the tumour is larger because of a diagnostic delay resulting in a worse prognosis. Among stage I patients we found that the tumour size is larger among obese than among leaner women. This is in accordance with the results shown by Verreault et al. (1989) . Unfortunately, it is not possible to ascertain the tumour size as a variable in our analysis. However, this has been done by Boyd et al. (1981) . They found that the prognostic effect of weight could not be explained by differences in clinical stage using the TNM classification (UICC, 1986) or histological grade of the tumour. This indicates that the effect of obesity on breast cancer prognosis is not an artefact of delayed diagnosis in overweight patients. Another support for this statement is given by Verreault et al. (1989) . They found among patients with oestrogen receptor positive tumours the percentage with involved nodes at diagnosis increased with increasing Quetelet's index after adjustment for tumour size. There was no, or little, association between Quetelet's index and oestrogen receptor status or with any of the measured histological features of the breast tumour like mitotic activity and nuclear size.
While previous studies have computed Quetelet's index on the basis of patients' weight at the time of diagnosis, this study is based on height and weight measurement prior to the diagnosis. However, the similarity between our results and those from previous studies indicate that the time of height and weight measurements has little effect on the pattern of association. This is confirmed by our finding that the prognostic effect of premorbid body mass index did not depend on the length of time between measurement and diagnosis.
Age was found to be a prognostic factor for breast cancer patients in stages I and II. From a statistical point of view, the absence of the effect of age in stages III and IV can by chance be a result of small numbers. However, the same observation was made in previous studies at the Cancer Registry of Norway (1980) and the explanation may be that women diagnosed in stage III and especially in stage IV are in such a serious condition that the age is of minor importance for the outcome of the disease. Subgroup analysis by age revealed that overweight is a prognostic factor both in pre-as well as post-menopausal age. This is partly in contrast with the conclusions of Boyd et al. (1981) who found that the effect was most marked in post-menopausal women. This disagreement may be caused by differences in the definition of overweight. We think that a woman's body mass changes with age, not only because of change in caloric intake or physical activity. Our definition is therefore a consequence of this view.
Wynder and Cohen (1982) discussed in an editorial the rationale of dietary intervention in the treatment of postmenopausal breast cancer patients. They suggested a randomised prospective clinical trial with the control group consuming their customary diet and the experimental group a modified diet based on the Japanese model. They also suggested that the trial group should be limited to post-menopausal patients in stage II, because this subgroup has been shown to be most resistant to chemotherapy. Our study supports the findings that the prognostic effect expressed as the absolute difference in survival between the lowest and highest quintile is largest for patients in stage II, but the results do not indicate that the trial group should necessarily be restricted to post-menopausal women. Since the relative prognostic effect is greatest for patients in stage I and they represent about 50% of all breast cancer patients, the inclusion of these patients in the trial group should be discussed.
Our study indicates that in a possible dietary intervention trial we should use our resources mainly on women belonging to the fifth quintile of Quetelet's index relative to their age. Dietary intervention should make breast cancer patients in the fifth quintile lose weight down to the level of those in the fourth quintile. That means a weight reduction of 8-1O kg. For example, a 60-year-old woman, 160 cm tall, having a Quetelet's index of 3.25 g cm-2, has to slim down from 83.2 kg to 75.5 kg.
The feasibility of an intervention trial depends on the possibility to include enough patients and to obtain enough resources to slim down the women by about 10% of their weight and to keep them at that level of weight. In Table III it is demonstrated that a trial based on one year's inclusion of patients in stage II (design a) would require 900 patients from a background breast cancer population of minimum 17,000 cases (All ages). This illustrates the amount of resources needed to carry out a trial with a reasonable precision. If the trial group includes patients in stage I as well as stage II (design b), then the number of patients needed will be doubled, while the minimum size of the background breast cancer population would decrease to 14,690. This means that in designs (a) and (b) the minimum number of patients in the background breast cancer population are about the same size, while the need of resources will be doubled by using design (b) instead of design (a). There may be other designs than those mentioned here, but these examples may illustrate the scope for such a trial.
As mentioned, Verreault et al. (1989) found that the percentage of patients with involved lymph nodes at diagnosis increased significantly with overweight. This was true mainly for women with a positive oestrogen receptor status. An implication of this observation could be that overweight is only a prognostic factor for patients having a positive oestrogen receptor status. We have no data to examine this hypothesis, but if this is true, it might be possible to define a subgroup where overweight as a prognostic factor would be even stronger than demonstrated in our study.
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